New consensus statement provides guidance for use of 177Lu-PSMA radionuclide therapy in mCRPC patients
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy. The statement, published in the July issue of The Journal of Nuclear Medicine, also reviews current clinical struggles … Read more